Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Patient and UCB Unit Selection:~Inclusion Criteria: General (Adults and Pediatrics)~Only one of the following should be present:~* Acute leukemia (lymphocytic or myeloid or undifferentiated or biphenotypic) in complete remission 2 or beyond~* Acute lymphocytic leukemia, Philadelphia chromosome positive in complete remission 1 or beyond~* Acute myeloid leukemia in complete remission 1 if it has evolved from a myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS).~* Acute leukemia in complete remission 1 if there is a failure to recover normal blood counts or the development of MDS following induction chemotherapy.~* Therapy related acute leukemia in complete remission 1 or beyond~* Chronic myeloid leukemia (CML) chronic phase-1 (imatinib failures, imatinib intolerance), or any CML beyond first chronic phase~* Myelodysplastic syndromes (Intermediate -1 or higher risk by IPSS)~* Therapy related MDS (irrespective of IPSS)~* Multiple myeloma must have had prior chemotherapy or autologous transplant~* Chronic lymphocytic leukemia must have failed two lines of conventional therapy but still chemosensitive to third line therapy.~* Chemosensitive Non-Hodgkin's lymphoma or Hodgkin's lymphoma in CR or PR after failing induction therapy.~* High risk acute leukemia/lymphoma eg Nk/T cell, HTLV associated leukemia/lymphoma, other T cell lymphoma/leukemia in first best response~* For patients with acute leukemia-they must be in a remission (less than 5% leukemic marrow blasts) at time of study entry.~Inclusion Criteria (Adults - 18 years or older)~* Karnofsky score of \> 70%~* Estimated creatinine clearance of \> 60 ml/min~* Left ventricular ejection fraction of \>50%~* Pulmonary function test with DLCO, FEV1 and FVC of \>60%~* Total bilirubin and SGOT of \< 3.0 x upper limits of normal~* Note: Age 18- 40 years for adult myeloablative conditioning Age \> 40 -50 years for adult reduced intensity conditioning~Inclusion Criteria (Pediatrics - 18 years and younger)~* Karnofsky or Lansky score of \> 70%~* Estimated Creatinine clearance of \> 60 ml/min~* Left ventricular ejection fraction of \>50%~* Pulmonary function test with FEV1 and FVC of \>60% (for patients \>6 years of age)~* Total bilirubin and SGOT of \< 3.0 x upper limits of normal~* Note: All pediatric patients will receive myeloablative conditioning~Inclusion Criteria - Donor Issues~* No available HLA identical or 1 antigen/allele mismatched (Class I-A, B or Class II DR locus) related donor~Inclusion Criteria: Umbilical Cord Blood Unit-HLA Typing~* At least a HLA 4/6 match (Class I-A, B by low resolution, Class II-DR by high resolution) to recipient~* For double UCB SCT each unit should be at least a 4/6 match (Class I-A,B by low resolution, Class II-DR by high resolution) to recipient, and should be at least a 4/6 match (Class I-A,B by low resolution, Class II-DR by high resolution) to each other~Inclusion Criteria: Umbilical Cord Blood Unit-Cell dose~* For Single UCB SCT: the unit will have ≥ 3.5 X 107 NC/kg of recipient body weight (For pediatric patients a cell dose ≥ 3.0 X 107 NC/kg of recipient body weight is acceptable). Recipient body weight will be determined as per standard guidelines.~* For Double UCB SCT: (done only if no single UCB unit ≥ 3.5 X 107 NC/kg of recipient body weight is available for adults, and ≥ 3.0 X 107 NC/kg of recipient body weight is available for pediatric patients )~* The larger of the two units (UCB1) will have a minimum cell dose of 2.0 X 107 NC/kg of recipient body weight. The smaller of the two units (UCB2) will have a minimum of 0.5 X 107 NC/kg of recipient body weight.~The total cell dose UCB1 + UCB2 will be ≥ 2.5 X 107 NC/kg of recipient body weight.~-Adult patients eligible for a double UCB SCT but without an appropriate second UCB unit will be enrolled in the study if their single UCB unit contains ≥ 2.5 x 107 NC/kg recipient body weight.~Exclusion Criteria~* Organ dysfunction as per standard guidelines. Unable to give informed consent (for adults only)~* Pregnant or lactating~* Sexually active individuals capable of becoming pregnant or causing a pregnancy who are unable or unwilling to use appropriate contraceptives.~* Active use of illicit drugs as evidenced by a positive toxicology screen for a substance not prescribed by a medical professional just prior to initiating the preparative regimen~* Actively smoking as evidenced by a positive nicotine screen just prior to initiating the preparative regimen~* HIV positive~* Patients with other unrelated malignancies will be excluded except:~* diagnosis of skin cancer (squamous cell or basal cell)~* diagnosis of cervical dysplasia (CIN I-III)~* any other malignancy which is currently in remission and was treated with curative intent more than 5 years preceding study entry~* In patients with secondary MDS or secondary acute leukemias-the previous non-hematopoietic neoplasm should be in remission but can be within 5 years of study entry

- Gender: ALL
- Minimum Age: None
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pediatric Myeloablative conditioning (Type: EXPERIMENTAL): Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
- Adult Myeloablative conditioning (Type: EXPERIMENTAL): Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
- Reduced-intensity conditioning (Type: EXPERIMENTAL): Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.

Based on this trial design, predict the completion outcome and termination type (if applicable).